BioSyent Inc. (TSXV:RX) is looking for acquisitions. Rene Goehrum, President and Chief Executive Officer said during the Fourth Quarter and Fiscal Year 2023 Results Presentation, "So growth drivers, not just in 2024, but '25 and '26. We are working on additional acquisition and in-licensing opportunities and enhanced focus on acquisitions, so in-market assets that are revenue generating, but we do have a few assets in either negotiation or diligence at this stage, and we expect to be able to share more about that as the year progresses".
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10 CAD | +2.46% | -3.57% | +8.46% |
May. 17 | Tranche Update on BioSyent Inc. (TSXV:RX)'s Equity Buyback Plan announced on December 13, 2023. | CI |
May. 17 | BioSyent Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.46% | 83.11M | |
+56.89% | 809B | |
+39.52% | 624B | |
-6.55% | 351B | |
+7.92% | 289B | |
+13.74% | 240B | |
+13.83% | 220B | |
-0.49% | 219B | |
+7.94% | 166B | |
-2.57% | 157B |
- Stock Market
- Equities
- RX Stock
- News BioSyent Inc.
- BioSyent Inc. Seeks Acquisitions